<DOC>
	<DOCNO>NCT01353248</DOCNO>
	<brief_summary>The purpose phase 2 study determine whether 30 mg 90 mg GS-5885 give GS-9451 , Tegobuvir Ribavirin ( RBV ) 12 24 week effective , safe tolerable treatment Chronic Genotype 1 HCV Infection .</brief_summary>
	<brief_title>GS 5885 Administered Concomitantly With GS-9451 , Tegobuvir Ribavirin ( RBV ) Chronic Genotype 1 Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Adult subject 18 70 year age Chronic HCV infection least 6 month prior Baseline ( Day 1 ) Liver biopsy result ( performed 2 year prior Screening ) indicate absence cirrhosis Monoinfection HCV genotype 1a 1b HCV treatmentnaïve Body mass index ( BMI ) 18 36 kg/m2 Creatinine clearance ≥ 50 mL/min Subject agree use highly effective contraception method female childbearing potential sexually active male . Screening laboratory value within define threshold Autoimmune disease Decompensated liver disease cirrhosis Poorly control diabetes mellitus Severe psychiatric illness Severe chronic obstructive pulmonary disease ( COPD ) Serological evidence coinfection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , another HCV genotype Suspicion hepatocellular carcinoma malignancy ( exception certain skin cancer ) History hemoglobinopathy Known retinal disease Subjects immunosuppressed Subjects know , current use amphetamine , cocaine , opiate ( i.e. , morphine , heroin ) , methadone , ongoing alcohol abuse Subjects must history clinically significant cardiac disease , include family history Long QT syndrome , relevant electrocardiogram ( ECG ) abnormalities screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>GS-5885</keyword>
	<keyword>GS-9451</keyword>
	<keyword>Tegobuvir</keyword>
</DOC>